Drug Profile
Telisotuzumab vedotin - AbbVie
Alternative Names: ABBV-399; ABT 399; Teliso-V; Telisotuzumab-vedotinLatest Information Update: 01 Dec 2023
Price :
$50
*
At a glance
- Originator AbbVie
- Developer AbbVie; Bristol-Myers Squibb
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Peptides
- Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-met inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- No development reported Solid tumours
- Discontinued Squamous cell cancer
Most Recent Events
- 29 Nov 2023 Adverse events and efficacy data from phase II trial in Non-small cell lung cancer released by Abbvie (IV)
- 23 Oct 2023 AbbVie plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or better) in unknown location (IV, Infusion) (NCT06093503)
- 20 Oct 2023 Efficacy data from phase II LUMINOSITY trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)